Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$26.12 - $34.07 $4,832 - $6,302
-185 Reduced 0.63%
29,214 $995,000
Q1 2024

May 14, 2024

BUY
$26.64 - $40.31 $13,826 - $20,920
519 Added 1.8%
29,399 $1.03 Million
Q4 2023

Feb 15, 2024

BUY
$19.95 - $31.0 $3,551 - $5,518
178 Added 0.62%
28,880 $834,000
Q3 2023

Nov 14, 2023

BUY
$21.33 - $59.42 $56,097 - $156,274
2,630 Added 10.09%
28,702 $657,000
Q2 2023

Aug 14, 2023

BUY
$34.33 - $62.11 $588,107 - $1.06 Million
17,131 Added 191.6%
26,072 $1.49 Million
Q1 2023

May 15, 2023

BUY
$26.01 - $48.69 $12,198 - $22,835
469 Added 5.54%
8,941 $336,000
Q4 2022

Feb 14, 2023

BUY
$24.14 - $30.37 $7,459 - $9,384
309 Added 3.79%
8,472 $226,000
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $11,893 - $17,852
535 Added 7.01%
8,163 $231,000
Q2 2022

Aug 22, 2022

BUY
$19.74 - $43.01 $1,085 - $2,365
55 Added 0.73%
7,628 $165,000
Q1 2022

May 16, 2022

BUY
$36.25 - $52.02 $6,235 - $8,947
172 Added 2.32%
7,573 $304,000
Q4 2021

Feb 14, 2022

BUY
$43.27 - $65.72 $2,293 - $3,483
53 Added 0.72%
7,401 $350,000
Q3 2021

Nov 15, 2021

BUY
$53.61 - $67.5 $188,868 - $237,802
3,523 Added 92.1%
7,348 $416,000
Q2 2021

Aug 12, 2021

BUY
$45.13 - $64.99 $52,260 - $75,258
1,158 Added 43.42%
3,825 $220,000
Q1 2021

May 17, 2021

BUY
$29.77 - $84.85 $7,948 - $22,654
267 Added 11.13%
2,667 $169,000
Q4 2020

Feb 12, 2021

BUY
$25.66 - $34.55 $18,475 - $24,875
720 Added 42.86%
2,400 $80,000
Q3 2020

Nov 13, 2020

SELL
$22.51 - $30.11 $13,033 - $17,433
-579 Reduced 25.63%
1,680 $46,000
Q2 2020

Aug 14, 2020

BUY
$12.65 - $29.57 $8,184 - $19,131
647 Added 40.14%
2,259 $61,000
Q1 2020

May 14, 2020

BUY
$10.84 - $20.85 $6,720 - $12,927
620 Added 62.5%
1,612 $24,000
Q4 2019

Feb 13, 2020

BUY
$13.02 - $19.5 $2,369 - $3,549
182 Added 22.47%
992 $17,000
Q3 2019

Nov 13, 2019

BUY
$17.46 - $29.05 $14,142 - $23,530
810 New
810 $15,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.